Disease Management : Separating Fact From Fantasy. Conference. Tucson, Arizona (USA), 1996/01/23.
Although the data at the outset of a contractual agreement can often be incomplete or inaccurate, and the analytical tools necessary to interpret these data are still being developed, partners about to enter a disease management (DM) arrangement can nonetheless take steps to ensure that the relationship will be sound and successful.
Pharmaceutical firms (and other service providers) wishing to enter into DM relationships with managed-care organizations must consider several important factors of the contracting process to protect their financial interests and benefit from the partnership, particularly in the first 1 to 2 years of the arrangement.
This paper provides recommendations for both general strategies and financial elements of DM contracting, and defines several contractual elements that can help to secure a harmonious and profitable partnership.
These suggestions address concerns for various types of partnerships, including risk-sharing and fee-for-service plans.
Early and careful consideration of the legal aspects of the DM business can protect companies from incurring significant, unanticipated losses.
Mots-clés Pascal : Médicament, Chimiothérapie, Traitement, Contrat, Législation, Recommandation, Economie santé, Politique sanitaire, Etats Unis, Amérique du Nord, Amérique, Choix, Coût, Homme
Mots-clés Pascal anglais : Drug, Chemotherapy, Treatment, Contract, Legislation, Recommendation, Health economy, Health policy, United States, North America, America, Choice, Costs, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0159947
Code Inist : 002B02A07. Création : 21/05/1997.